CLINICAL TRIALS PROFILE FOR ULIMORELIN

Clinical Trials for Ulimorelin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01285570 ↗	Ulimorelin Study of Efficacy and Safety (ULISES 007)	Completed	Norgine	Phase 3	Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.
NCT01285570 ↗	Ulimorelin Study of Efficacy and Safety (ULISES 007)	Completed	Tranzyme, Inc.	Phase 3	Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.
NCT01296620 ↗	Ulimorelin Study of Efficacy and Safety (ULISES 008)	Completed	Norgine	Phase 3	Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection

Clinical Trial Conditions for Ulimorelin

Condition Name

Condition Name for
Intervention	Trials
Gastrointestinal Dysmotility	2
Digestive System Disorders	2
Enteral Feeding Intolerance (EFI)	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Gastrointestinal Diseases	2
Digestive System Diseases	2
Liver Diseases	1

Clinical Trial Locations for Ulimorelin

Trials by Country

Trials by Country for
Location	Trials
United States	33
Romania	2
United Kingdom	2
Serbia	1
Bulgaria	1

Trials by US State

Trials by US State for
Location	Trials
New York	2
Texas	2
North Carolina	2
Mississippi	2
Oregon	2

Clinical Trial Progress for Ulimorelin

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	1
Phase 1	3

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	7

Clinical Trial Sponsors for Ulimorelin

Sponsor Name

Sponsor Name for
Sponsor	Trials
Norgine	5
Tranzyme, Inc.	2
Lyric Pharmaceuticals	2

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	9